Holen Sie sich die Stockscreener-App
5.605
0.53%
-0.065
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - pharmiweb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences: Q4 Earnings Snapshot - Bluefield Daily Telegraph
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Yahoo! Finance Canada
Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus
Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia
Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Nigeria
Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com
Precision BioSciences receives U.S. patent allowances covering the PBGENE-HBV program - marketscreener.com
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - TradingView
Patent nod through 2044 backs hepatitis B gene edit program - Stock Titan
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - BioSpace
Precision BioSciences Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Precision BioSciences (DTIL) Presents Promising Preclinical Data for DMD Therapy - GuruFocus
Precision BioSciences presents preclinical data on DMD therapy - Investing.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - BioSpace
Precision BioSciences to Report Q4 and Fiscal Year 2025 Results - National Today
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - BioSpace
Precision BioSciences Says PBGENE-DMD Receives FDA Fast Track Designation - marketscreener.com
Precision BioSciences stock jumps on FDA Fast Track status By Investing.com - Investing.com Canada
FDA Grants Fast Track Status to Precision BioSciences' (DTIL) PB - GuruFocus
Earnings Beat: Is Precision BioSciences Inc stock trending bullishPortfolio Update Summary & Real-Time Volume Triggers - baoquankhu1.vn
Market Outlook: Is Precision BioSciences Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Fast Gain Swing Alerts - Naître et grandir
Guidance Update: What is the long term forecast for Precision BioSciences Inc stockWeekly Trade Analysis & Verified Short-Term Trading Plans - baoquankhu1.vn
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Intellectia AI
Risk Off: Whats the outlook for Precision BioSciences Incs sectorMarket Growth Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Precision BioSciences: $7.5 Million Milestone From TG Therapeutics For Azer-Cel Clinical Progress In Multiple Sclerosis - Pulse 2.0
Forecast Cut: What is the long term forecast for Precision BioSciences Inc stockInsider Selling & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - 01net
Aug Macro: How does Precision BioSciences Inc compare to its peers2025 Price Momentum & Real-Time Volume Analysis - baoquankhu1.vn
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch? - AD HOC NEWS
Stock Analysis: How does Precision BioSciences Inc compare to its peersInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DTIL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Block Trades: Is Precision BioSciences Inc a speculative investmentBear Alert & Expert Approved Trade Ideas - baoquankhu1.vn
Precision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15 - MSN
What’s the outlook for Precision BioSciences Inc.’s sector2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares - MarketBeat
John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat
Precision Biosciences (DTIL) CFO logs RSU vesting and tax sell-to-cover - Stock Titan
Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock - MarketBeat
DTIL (NASDAQ: DTIL) trustee sold 10,200 shares; 4,925 vesting reported - Stock Titan
FDA Clears ARCUS Editor for Duchenne Hot-spot - CRISPR Medicine News
Top 15 Female Motivational Speakers in the UK Revealed in 2026 Shortlist - Weekly Voice
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
Lynx1 discloses 4.1% Precision BioSciences (DTIL) stake in Schedule 13G/A - Stock Titan
Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial - Indian Pharma Post
DTIL PE Ratio & Valuation, Is DTIL Overvalued - Intellectia AI
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):